|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-macrophage progenitors assayed as colony-forming unit granulocyte/macrophage (CFU-GM) in spleen were markedly increased in number by Hu-G-CSF, and the accelerated recovery from neutropenia may be due to the stimulation of granulocytopoiesis by the G-CSF from progenitor cells.
|
3115920 |
1987 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression.
|
7688884 |
1993 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression.
|
7688884 |
1993 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
|
7524159 |
1994 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
|
7524159 |
1994 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
|
7543699 |
1995 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy.
|
7529132 |
1995 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
|
7543699 |
1995 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy.
|
7529132 |
1995 |
|
Neutropenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intravenous gammaglobulin did not lead to resolution of his neutropenia; G-CSF was also necessary.
|
8669967 |
1996 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human granulocyte colony-stimulating factor treatment resulted in dramatic improvement of neutropenia and morbidity.
|
8989458 |
1996 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent reports suggest that a beneficial effect may be observed in the administration of hematopoietic growth factors (G-CSF, GM-CSF) for patients with DC and neutropenia.
|
9773234 |
1998 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Successful treatment of pustulosis palmaris et plantaris with granulocyte colony stimulating factor in a patient with hereditary neutropenia.
|
9885446 |
1998 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
All patients received granulocyte colony-stimulating factor (G-CSF) beginning on the day after paclitaxel and lasting until recovery from neutropenia.
|
9774950 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human recombinant granulocyte colony-stimulating factor (G-CSF) has become a treatment of choice for neutropenia of diverse etiologies.
|
9760159 |
1998 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent large, painful oral ulcerations can occur that are not necessarily associated with neutropenia nor do they respond to granulocyte colony-stimulating factor administration.
|
9486673 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
|
9740541 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
All patients received granulocyte colony-stimulating factor (G-CSF) beginning on the day after paclitaxel and lasting until recovery from neutropenia.
|
9774950 |
1998 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
|
9740541 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A slight neutropenia was present 48 hours after the application of filgrastim.
|
11005621 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The associated neutropenia can be partially corrected by treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
10607719 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant granulocyte colony-stimulating factor induces production of human neutrophil peptides in lung cancer patients with neutropenia.
|
11062337 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Supportive measures include the use of granulocyte colony-stimulating factor (5 microg/kg/d) to limit neutropenia.
|
10877051 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Five patients experienced febrile neutropenia, which was successfully treated with G-CSF and broad-spectrum antibiotics.
|
11712802 |
2001 |
|
Neutropenia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Five patients experienced febrile neutropenia, which was successfully treated with G-CSF and broad-spectrum antibiotics.
|
11712802 |
2001 |